We are live on ! Find out more
BSTC

BioSpecifics Technologies Corp.
BSTC

Delisted

BSTC was delisted on the 1st of December, 2020.

114 hedge funds and large institutions have $259M invested in BioSpecifics Technologies Corp. in 2019 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 51 increasing their positions, 34 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 34

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 16

2% less capital invested

Capital invested by funds: $264M → $259M (-$5.37M)

3% less funds holding

Funds holding: 117114 (-3)

Holders
114
Holders Change
-3
Holders Change %
-2.56%
% of All Funds
2.48%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
16
Increased
51
Reduced
34
Closed
16
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Bank of America
76
Bank of America
North Carolina
$255K +$90.9K +1,444 +51%
Manulife (Manufacturers Life Insurance)
77
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$245K +$258K +4,104 New
Barclays
78
Barclays
United Kingdom
$236K +$120K +1,902 +93%
AIG
79
American International Group
New York
$233K +$14.5K +231 +6%
Janus Henderson Group
80
Janus Henderson Group
United Kingdom
$207K -$8.87K -141 -4%
SI
81
Shaker Investments
Ohio
$205K +$216K +3,425 New
MIM
82
MetLife Investment Management
New Jersey
$181K
Bank of Montreal
83
Bank of Montreal
Ontario, Canada
$151K -$161K -2,565 -51%
FQ
84
First Quadrant
California
$147K
MLICM
85
Metropolitan Life Insurance Company (MetLife)
New York
$125K
MAM
86
Meeder Asset Management
Ohio
$123K -$12.8K -204 -9%
ADEF
87
Adams Diversified Equity Fund
Maryland
$107K -$75.5K -1,200 -40%
Citigroup
88
Citigroup
New York
$102K +$15.4K +244 +17%
Victory Capital Management
89
Victory Capital Management
Texas
$87K -$159K -2,521 -63%
Legal & General Group
90
Legal & General Group
United Kingdom
$81K +$8.68K +138 +11%
APA
91
American Portfolios Advisors
New York
$64.2K -$1.51K -24 -2%
US Bancorp
92
US Bancorp
Minnesota
$58K -$36.2K -576 -37%
AIM
93
Advantage Investment Management
Iowa
$57K +$17.5K +278 +41%
Canada Life
94
Canada Life
Manitoba, Canada
$55K +$58K +922 New
FANJ
95
Financial Architects (New Jersey)
New Jersey
$54K +$28.3K +450 +98%
AG
96
Advisor Group
Arizona
$44K +$22.4K +356 +94%
Morgan Stanley
97
Morgan Stanley
New York
$40K -$985K -15,656 -96%
BNP Paribas Financial Markets
98
BNP Paribas Financial Markets
France
$38.9K -$34.8K -553 -46%
AIP
99
Ameritas Investment Partners
Nebraska
$30K
Federated Hermes
100
Federated Hermes
Pennsylvania
$24K -$3.02K -48 -11%

BSTC Hedge Fund Activity: Q2 2019 in Review

114 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in BioSpecifics Technologies Corp. (BSTC) for Q2 2019, worth a combined $259M — down 2% from $264M a quarter earlier.

Fund positioning in BSTC was balanced in Q2 2019: 16 funds opened new positions, 16 closed out, 51 added to existing stakes and 34 trimmed.

The largest buyer was Nuveen, opening a new position worth an estimated $4.49M. The largest seller was Acadian Asset Management, exiting entirely with an estimated $9.02M sold.

  • 114 institutional investors held BioSpecifics Technologies Corp. (BSTC) as of Q2 2019, down from 117 in Q1 2019.
  • Funds reported $259M of BioSpecifics Technologies Corp. stock for Q2 2019, down 2% quarter-over-quarter.
  • 16 funds opened new BioSpecifics Technologies Corp. positions in Q2 2019 and 16 closed out, a net change of 0 holders.
  • The largest BioSpecifics Technologies Corp. buyer in Q2 2019 was Nuveen, an estimated $4.49M added.
  • The largest BioSpecifics Technologies Corp. seller in Q2 2019 was Acadian Asset Management, an estimated $9.02M sold.

Based on aggregated 13F filings for Q2 2019.